In a report published Tuesday, Morgan Stanley analyst Bin Li reiterated an Overweight rating on Sinovac Biotech Ltd. SVA, but removed the $9.00 price target.
In the report, Morgan Stanley noted, “Sinovac's 1Q14 EPS of US$0.00 was above our -US$0.01 estimate on higher hepatitis sales and gross margin. We are pleased to see more tender orders, positive progress of EV71 vaccine and continuous advance of its product pipeline, which should support top-line growth ahead.
1Q14 total sales of US$13.5mn (+34% YoY) topped our forecast by 8% on higher Bilive (Hep A+B vaccine) revenue of US$6.0mn (+100% YoY from US$3mn in 1Q13), partially offset by slower influenza sales of US$61K (vs. our US$0.3mn estimate), as 1H is normally the slowest season for flu vaccines.”
Sinovac Biotech Ltd. closed on Friday at $6.02.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in